Derek Archila

Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa.  The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...

Despite the recent upward momentum in Pacira Pharmaceuticals Inc (NASDAQ: PCRX) shares, Stifel is taking a bearish stance on the stock.  The Analyst Analyst Derek Archila initiated coverage of Pacira with a Sell rating and $41 price target. The Thesis The recent rally in Pacira...

Shares of DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT), a clinical-stage biotech developing treatment options for food allergies, present a favorable risk-reward profile over the next 12 months, according to Stifel. The Analyst Analyst Derek Archila initiated coverage of DBV Tech with a Buy rating and...

The FDA dealt yet another blow to struggling Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) investors by approving rival Mylan N.V. (NASDAQ: MYL)’s generic version of Teva’s Copaxone multiple sclerosis drug. Analysts say generic competition was not factored into Teva’s...

Based on the nearly 25-percent decline in Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock price on Thursday, some investors and analysts have legitimate concerns over the company's earnings report and outlook. Among those on Wall Street who share this concern include...

Oppenheimer remains Outperform-rated on Mallinckrodt PLC (NYSE: MNK) saying near-term concerns over Acthar competition are overblown, as he expressed confidence in Acthar's durability. The brokerage, which has a $72 price target on Mallinckrodt shares, said the company’s key brands,...

Oppenheimer said in a note on Wednesday Insys Therapeutics Inc (NASDAQ: INSY) maintains its potential long-term upside. However, the firm said it prefers to be on the sidelines for now. DoJ Investigation Resolution Awaited Analyst Derek Archila said he continues to rate Insys at Perform, as...